Sept. 14 (Bloomberg) -- Makers of antidepressants including Pfizer Inc., Wyeth and GlaxoSmithKline Plc should be required to put stronger warning labels on their drugs, a U.S. advisory panel said.

A Food and Drug Administration commission voted 27-0 to tell the agency that risk warnings should be strengthened for all nine drugs in the review. The panel also voted 25-1, with one abstention, to find that antidepressants may raise the risk of suicidal behavior in children and teenagers. The voting came during two days of hearings in Bethesda, Maryland.